Assembly Biosciences Inc. (ASMB) Next Earnings Date & Expected ±10.4% Move

Per the Roarable RQD rating, ASMB scores 16 out of 100 for a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 2 of 20 (ROIC -6.5%; FCF yield -9.69%), indicating the business is not currently generating economic returns or free cash flow relative to its market value. Whale 13F Flow scores 3 of 20 (institutional accumulation and options positioning), Insider Conviction scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 3 of 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 5 of 20 (Altman Z 1.57; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillar is the cash engine, which is the most direct driver of intrinsic value; the forensic balance sheet is the strongest of the five but remains weak in absolute terms. For a prospective investor, the upside case rests on the pipeline catalysts in the news wire, while the valuation tradeoff is that the current price of $20.86 is not supported by the reported cash generation in the sources. The rating's implication is elevated forensic risk, and any position should be weighed against the negative FCF and negative margins shown in the financials.

Assembly Biosciences Inc. (ASMB) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company carries a market capitalization of $0.4B. Per the news wire, its disclosed development focus includes an oral NTCP inhibitor, ABI-6250, being studied in chronic hepatitis delta virus (HDV). The sources do not describe its customers or detail how it earns revenue beyond reported figures.

Per the SEC financials, revenue rose from $28.5M in FY 2024 to $72.3M in FY 2025, and net loss narrowed from $-40.2M to $-6.1M. Per the market data, operating margin is -16.8%, net margin is -8.5%, gross margin is 0%, and ROIC is -6.5%. Per the Roarable RQD rating, the Altman Z-Score is 1.57 and the Piotroski F-Score is 3/9, with a Debt/Equity of 0.5. Reported FCF remained negative in FY 2025 at $-41.2M, so the balance sheet's cash position of $58.5M is being drawn down rather than replenished by operations.

• Phase 2 dosing (catalyst): The news wire reports that ASMB has begun Phase 2 trial dosing for ABI-6250 in chronic HDV, and a separate item reports dosing of the first two participants. This is the most material development in the sources.
• Once-daily positioning: A Stock Titan item describes the candidate as a once-daily oral drug for hepatitis D, contrasted with an approved treatment that requires daily injections.
• Market-wire items: Several items are routine market-action reports (seasonal returns charts) with no company-specific fundamental content.
• Sector-screen item: A TradingView item on healthcare stocks with revenue growth and attractive valuations is classed as a catalyst, but it does not name a company-specific driver.
• Proprietary signals: Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Risk watch items: the sources contain no trial readout timing, efficacy data, or regulatory milestones, so the catalyst's ultimate significance cannot be assessed from the data.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The sources therefore do not identify upstream suppliers, downstream customers, or sector correlations. A prospective investor should note that the absence of mapped links means second-order ripple effects cannot be traced from the provided data; the only observable linkage is the shared Health Care sector and Biotechnology industry classification.

• What are the timing and endpoints of the Phase 2 study of ABI-6250 in chronic HDV, and when are data expected?
• What drove FY 2025 revenue growth to $72.3M, and is that revenue recurring or one-time?
• What is the company's debt position, given the source reports debt as N/A across all periods?
• What is the forward earnings and cash-burn outlook, given reported FCF has been negative in each period shown except FY 2023?
• Who are the institutional and insider holders, given the holders section is NONE?